Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin

NCT03388190 is registered in ClinicalTrials.gov with University Hospital, Akershus as lead sponsor.

NCT NCT03388190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03388190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
Lead sponsor
University Hospital, Akershus
Phase
Phase 2
Overall status
Completed
Start date
May 29, 2018
Completion date
March 18, 2024
Enrollment
80 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer metastatic